Azathioprine administration to NZB X NZW hybrid mice with lupus nephritis: beneficial effect complicated by development of malignant lymphomas.
D000818:Animals; D001323:Autoantibodies / Q000096:biosynthesis; D001327:Autoimmune Diseases / Q000097:blood / Q000188:drug therapy / Q000276:immunology / Q000401:mortality / Q000473:pathology / Q000517:prevention & control; D001379:Azathioprine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001835:Body Weight; D005260:Female; D006689:Hodgkin Disease / Q000139:chemically induced*; D007668:Kidney / Q000473:pathology; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000473:pathology; D008221:Lymphoid Tissue / Q000473:pathology; D051379:Mice; D009393:Nephritis / Q000097:blood / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality / Q000473:pathology / Q000517:prevention & control; D014508:Urea / Q000097:blood
D001323:Autoantibodies; D014508:Urea; D001379:Azathioprine